Applications of (2R,3S)-3-(Tert-Butoxycarbonyl)Amino-1,2-Epoxy-4-Phenylbutane in Industrial Manufacturing

As a manufacturer of specialty chiral intermediates, we supply (2R,3S)-3-(Tert-Butoxycarbonyl)Amino-1,2-Epoxy-4-Phenylbutane for advanced synthesis in pharmaceutical actives, peptide building, and other fine chemical applications. The following sections present real-world industrial usage scenarios, specific process integrations, and downstream market requirements.

1. Active Pharmaceutical Ingredient (API) Chiral Intermediate Production

Major pharmaceutical companies incorporate this compound as a chiral starter in the synthesis of complex APIs, including beta-amino alcohols and enantiomerically pure phenylbutane derivatives. Its protected amino-epoxy structure streamlines multi-step synthesis, enhancing stereocontrol and impeding racemization during nucleophilic opening stages. Process chemists formulate batch reactions under ICH Q7 GMP regimes, using the compound in enantioselective benzylamine class API projects, particularly during nucleophilic epoxide opening prior to deprotection and downstream coupling. The resulting intermediates advance to late-stage crystallization and salt formation processes targeting oral solid dosage forms.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP-NF Monograph General Chapters: Synthesis and Purity
• EDQM CEP guidelines for chiral intermediates in API synthesis
• 21 CFR Part 211 Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs

Typical usage ratio

• 5–18% of total reaction mass, with adjustment based on molar stoichiometry and target enantiomer yield
• Mole-to-mole ratio relative to core aldehyde/ketone reactants varies with specific API structural design
• Protecting group stability allows for slightly higher input at scale-up to minimize side-product formation
• Engineer custom excess up to 25% under high-throughput conditions to ensure complete chiral conversion

Downstream process integration

• Added at primary nucleophilic ring opening under base-promoted conditions
• Typically resolved via column chromatography prior to acid-mediated Boc deprotection
• Feeds directly into amide coupling, reductive aminations, or carbamate transformation steps
• Chiral purity analysis conducted post-stage for QA release to formulation teams

Final product types

• Chiral pharmaceutical actives (e.g., beta-blockers, phenylbutylamines)
• Enantiopure pharmaceutical intermediates for branded drug synthesis
• Stereospecific bulk intermediates licensed for worldwide pharma markets
• Registered starting materials for equivalence filings in Europe and US

2. Peptidomimetic Building Block Integration

Peptide drug development leverages the protected amino-epoxybutane moiety to access constrained peptidomimetic structures. Research and production groups introduce the material into solid-phase peptide synthesis (SPPS) protocols or in solution-phase fragmentation. Its t-Boc amino protection ensures amino group stability under coupling and cyclization, while the epoxide acts as a reactive handle for site-specific ring-opening insertions. This enables the generation of conformationally restricted backbone modifications key for receptor selectivity and metabolic resistance in peptide therapeutics, especially for CNS and oncology indications. Downstream QA mandates tight verification of enantiopurity and residual protection group content per batch.

Industry compliance standards

• European Pharmacopoeia Monograph 2035 (Peptides)
• FDA 21 CFR 211 cGMP for peptide manufacturing
• ICH Q11: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)
• ISO 9001:2015 – Quality Management Systems for Fine Chemical Manufacturing

Typical usage ratio

• 1–8 mol% for incorporation at individual peptide elongation sites
• Higher (up to 20 mol%) for cyclic or constrained sequence libraries
• Load scaling defined by sequence length and desired side-chain insertion frequency
• Deprotection and post-cleavage typically require an excess for complete ring opening

Downstream process integration

• Solid-phase resin loading for on-bead modification and direct acylation
• Direct solution-phase insertion during fragment coupling
• Follows through to head-to-tail cyclization or N-terminus protection removal
• Purified via semi-preparative HPLC and tested for percent substitution per string

Final product types

• Peptidomimetic API candidates
• Cyclic and stapled peptide drug substances
• Custom research peptides for target discovery
• Metabolically stable peptide leads for clinical candidate selection

3. Chiral Auxiliary for Asymmetric Synthesis

Specialty fine chemical producers employ this compound as a chiral auxiliary in asymmetric ring-opening and nucleophilic addition processes. The epoxy and t-Boc-amino configuration imparts both enantioselectivity and functional protection for highly specific Grignard, reductive, or organocatalytic reactions. Customers in the pharmaceutical and agrochemical industries select this intermediate for use within non-racemic synthesis to achieve high optical purity in key intermediates, especially where subsequent deprotection under mild acidic conditions is feasible. Analytical QC at this stage includes chiral HPLC to document enantiomeric excess transfer from auxiliary.

Industry compliance standards

• Chemical Manufacturing ISO 9001:2015
• European REACH Registration for Fine Chemicals in Asymmetric Synthesis
• Applicable OECD Guidelines for chemical synthesis quality
• Company-specific validated synthesis SOPs

Typical usage ratio

• 10–25 mol% relative to limiting substrate
• Adjusted based on desired yield and optical isomer recovery rate
• Excess (up to 30 mol%) often introduced in scaling up for industrial batch reproducibility
• Post-reaction recovery of auxiliary allows for 60–80% recycling efficiency

Downstream process integration

• Added at initial steps for nucleophilic epoxide ring opening or Michael additions
• Allows stepwise control of chiral center formation
• Auxiliary removed or retained depending on downstream process needs
• Chiral purity checked by in-process HPLC/GC for QC sign-off

Final product types

• Chiral alcohols and amines for further transformation
• Agrochemical intermediates for fungicides or herbicides
• Building blocks for non-racemic cosmetic actives
• Custom organocatalyst ligands for contract research organizations

4. Pharmaceutical Analytical Reference Standard Synthesis

Analytical service laboratories use this compound as a precursor when preparing certified reference materials (CRMs) for chiral purity testing and enantiospecific quantification in regulatory submissions and routine batch QC. Synthesis teams convert the raw material into defined racemates and diastereomers under controlled acid/base or reductive conditions, isolating high-purity reference standards for subsequent NMR, LC-MS, and chiral HPLC calibration. Regulatory authorities and contract testing organizations require the availability of such reference materials for method validation, release testing of APIs, and impurity profiling under strict documentation and traceability frameworks.

Industry compliance standards

• ISO/IEC 17025:2017 Accreditation for testing and calibration laboratories
• USP <1086> Guidelines for Reference Standard Preparation
• European Pharmacopoeia General Method 2.2.24 (Chromatographic separation techniques)
• FDA Guidance for Industry: Analytical Procedures and Methods Validation

Typical usage ratio

• Used at 0.1–3 mmol scale for analytical reference synthesis per lot
• Excess quantities allocated for batch consistency verification
• Adjusted depending on the required number of CRM units and multi-method validations
• Lab-specific scaling for in-house or commercial reference production

Downstream process integration

• Initial batch compound subjected to defined derivatization or reduction
• Purification using preparative chromatography to HPLC-grade material
• Portioned and certified with NMR and mass spec validation
• Packaged for distribution to pharma QC, regulatory, and method validation units

Final product types

• Chiral purity reference standards for regulatory agencies
• Quantitative calibration materials for API batch release
• Validation kits for enantiospecific detection protocols
• Custom CRM blends for pharmaceutical development partnerships